Valdemar Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.40 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 0.30 M
- Revenue Growth -61.35%
- Profit Growth -88.61%
- Ebitda -100.08%
- Net Worth -927.95%
- Total Assets -17.77%
About Valdemar Pharma
Valdemar Pharma Private Limited (VPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 June 2010 and has a history of 14 years and seven months. Its registered office is in Thrissur, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M.
The company currently has active open charges totaling ₹0.30 M.
Mattappilly Mohandas and Mohanan Sukumaran serve as directors at the Company.
Company Details
-
Location
Thrissur, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51397KL2010PTC026213
-
Company No.
026213
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jun 2010
-
Date of AGM
25 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Valdemar Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mattappilly Mohandas
|
Managing Director | 21-Oct-2011 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Mohanan Sukumaran
|
Director | 18-Oct-2011 | Current |
Financial Performance of Valdemar Pharma.
Valdemar Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 61.35% decrease. The company also saw a substantial fall in profitability, with a 88.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 927.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Valdemar Pharma?
In 2019, Valdemar Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.30 M
₹0
Charges Breakdown by Lending Institutions
- Idbi Bank Limited : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Feb 2018 | Idbi Bank Limited | ₹0.30 M | Open |
How Many Employees Work at Valdemar Pharma?
Unlock and access historical data on people associated with Valdemar Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Valdemar Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Valdemar Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
